作者:Gunther Zischinsky、Frank Osterkamp、Doerte Vossmeyer、Grit Zahn、Dirk Scharn、Ariane Zwintscher、Roland Stragies
DOI:10.1016/j.bmcl.2009.10.073
日期:2010.1
Previous research within our laboratories identified the 3-hydroxypyrrolidine scaffold 1 as a new and selective integrin α5β1 inhibitor class which was designed for local administration. Herein the discovery of new orally available integrin α5β1 inhibitor scaffolds for potential systemic treatment is described.
我们实验室中的先前研究确定了3-羟基吡咯烷支架1是一种新型的选择性整联蛋白α5β1抑制剂,设计用于局部给药。本文描述了用于潜在全身治疗的新的口服整联蛋白α5β1抑制剂支架的发现。